.ANALYSIS EMPHASIZE.16 October 2024.
In the NIAGARA litigation, the addition of perioperative durvalumab to basic procedure for muscle-invasive sac cancer improved event-free and also in general survival, noting a brand-new procedure alternative for this problem.